Dr. Osborne obtained his BS with honors from Penn State University, his MD magna cum laude from Jefferson Medical College, and his PhD in cardiovascular physiology from Thomas Jefferson University. After graduation, he continued his post-doctoral studies at Harvard Medical School and Brigham and Women’s Hospital in Boston, Massachusetts where he completed his Internship, Residency and Research Residency in Internal Medicine and a Fellowship in Cardiovascular Disease. While at Harvard, Dr. Osborne published many articles on atherosclerosis, vascular biology, and molecular genetics. During his cardiology fellowship, he spent two years in the Department of Genetics at Harvard Medical School doing his post-doc in molecular genetics and positional clone genes for both Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. His clinical training focused on non-invasive techniques, and he is the
only physician board certified in Cardiology and Internal Medicine, Lipidology, Clinical Hypertension, Cardiac CT Angiography, Echocardiography and Nuclear Cardiology. His clinical interests include preventive cardiology, cardiometabolic disease, diabetes, hypertension, congestive heart failure, cholesterol disorders, cardiovascular genetics, cardiac AI-enhanced CT angiography, and identifying and implementing novel technologies for in-home and travel-related clinical services.
He is the founder and director of State of the Heart Cardiology in Southlake, Texas and is the Director of Cardiovascular CT at the Carrollton Regional Medical Center which just installed the nation’s first Atlas 960 640 Slice Cardiac CT Scanner. He is the consulting physician overseeing clinical medicine and innovation for Market Dynamics (now IQVIA In-home Clinical Services) for over 14 years, which focuses on life sciences consultancy services and has a nation-wide US presence to support in-office and in- home testing, medication initiation, and monitoring services.
His most current project is ClearCardioTM which is the nation’s leading preventive cardiology organizations which intends to eliminate cardiovascular disease by combining leading edge cardiovascular imaging with AI-based imaging analyses. These tools detect, quantify, and monitor cardiovascular disease and plaque to a degree never before possible. Utilizing state-of-the-art imaging with his knowledge of the variety of proven tools of plaque treatment, cardiovascular disease could be largely eliminated in the next few years.
He is also a consultant to a variety of innovative biotech companies that supply devices, AI, and ground-breaking technologies to provide cutting-edge medical care at home or anywhere in the world.
